前列腺SBRT后局部失败主要发生在前列腺影像报告和数据系统4或5分的主病灶内
本研究纳入2009至2018年在本院接受前列腺立体定向体部放疗(SBRT)的247例局限性前列腺癌患者,治疗后活检中位时间2.2年。结果显示39/247(15.8%)活检阳性,其中35/39(90%)治疗前存在主病灶(DIL),29/39(74.4%)复发位于DIL内。作者认为PI-RADS 4或5分DIL患者SBRT后局部复发风险更高,且多数复发位于DIL内。
要点
- 治疗后活检阳性39/247(15.8%),其中35/39(90%)治疗前存在DIL。
- 29/39(74.4%)阳性活检位于DIL内,提示复发多局限在主病灶区域。
- DIL存在与活检阳性独立相关(OR 6.95,p=0.001),SBRT剂量≥40 Gy(OR 0.26,p=0.003)和ADT使用(OR 0.28,p=0.027)与较低风险相关。
核心结论
- 作者认为,治疗前存在PI-RADS 4或5分DIL的男性接受前列腺SBRT后局部复发风险更高,且多数复发位于DIL内。
研究设计与样本
- 2009至2018年在本院接受前列腺SBRT的247例局限性前列腺癌患者,治疗后接受活检(活检中位时间2.2年)以评估局部控制。
- 前列腺SBRT中位剂量40 Gy分5次;MRI由一名对患者特征和治疗结局设盲的诊断放射科医师判读。
主要发现
- 247例接受治疗后活检的患者中,39例(15.8%)为可分级前列腺腺癌阳性,其中35/39(90%)治疗前存在DIL,29/39(74.4%)阳性活检位于DIL内。
- 与治疗后活检结局独立相关的因素包括:存在DIL(OR 6.95,p=0.001)、影像学T3病变(OR 5.23,p<0.001)、SBRT剂量≥40 Gy(OR 0.26,p=0.003)和使用雄激素剥夺治疗(ADT;OR 0.28,p=0.027)。
- 在存在DIL的患者(N=149)中,与治疗后活检结局相关的因素包括:≥50%穿刺针阳性(OR 2.4,p=0.037)、影像学T3病变(OR 4.04,p=0.001)、SBRT剂量≥40 Gy(OR 0.22,p<0.001)和使用ADT(OR 0.21,p=0.014)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A positive post-treatment prostate biopsy following definitive radiotherapy carries significant prognostic implications. OBJECTIVE: To determine whether local recurrences after prostate stereotactic body radiation therapy (SBRT) are associated with the presence of and occur more commonly within the region of a PI-RADS 4 or 5 dominant intra-prostatic lesion (DIL) identified on pre-treatment multi-parametric magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: 247 patients with localized prostate cancer treated with SBRT at our institution from 2009-2018 underwent post-treatment biopsies (median time to biopsy: 2.2 years) to evaluate local control. INTERVENTIONS: Prostate SBRT (median 40 Gy in 5 fractions). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: MRIs were read by a single diagnostic radiologist blinded to other patient characteristics and treatment outcomes. The DIL presence, size, location, and extent were then analyzed to determine associations with the post-treatment biopsy outcomes. RESULTS AND LIMITATIONS: Among patients who underwent post-treatment biopsies, 39/247 (15.8%) were positive for Gleason-gradable prostate adenocarcinoma, of which 35/39 (90%) had a DIL initially present and 29/39 (74.4%) had a positive biopsy within the DIL. Factors independently associated with post-treatment biopsy outcomes included the presence of a DIL (OR 6.95; p = 0.001), radiographic T3 disease (OR 5.23, p < 0.001), SBRT dose ≥40 Gy (OR 0.26, p = 0.003), and use of androgen deprivation therapy (ADT; OR 0.28, p = 0.027). Among patients with a DIL (N = 149), the only factors associated with post-treatment biopsy outcomes included ≥50% percent cores positive (OR 2.4, p = 0.037), radiographic T3 disease (OR 4.04, p = 0.001), SBRT dose ≥40 Gy (OR 0.22, p < 0.001), and use of ADT (OR 0.21, p = 0.014). CONCLUSIONS: Our results suggest that men with PI-RADS 4 or 5 DILs have a higher risk of local recurrence after prostate SBRT and that most recurrences are located within the DIL. PATIENT SUMMARY: We found the presence of a dominant tumor on pre-treatment MRI was strongly associated with residual cancer within the prostate after SBRT and that most recurrences were within the dominant tumor.
引用
- Gorovets D, Wibmer AG, Moore A, et al. Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion. Eur Urol Oncol. 2022. PMID: 35307323. doi:10.1016/j.euo.2022.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。